GlassScriptPhysician profile
Jessica L Halstead
NPI 1538536693
$10,525.24
in general payments reported to CMS, 2019-2025
32 companies · $2,568 in 2025
The $2,568 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,505 · 2022: $2,102 · 2023: $2,231 · 2024: $2,120 · 2025: $2,568.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,754 · Education: $165.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,753.71 |
| Education | $164.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,068.42 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Genentech USA, INC. | $1,806.80 | 2021-2025 | Xolair |
| Glaxosmithkline, LLC. | $1,612.38 | 2021-2025 | Nucala, Trelegy Ellipta |
| Regeneron Healthcare Solutions, INC. | $1,511.87 | 2021-2025 | Dupixent |
| Genzyme Corporation | $530.30 | 2021-2025 | |
| Abbvie INC. | $510.29 | 2022-2025 | |
| Incyte Corporation | $496.24 | 2022-2025 | Opzelura, Iclusig |
| Novartis Pharmaceuticals Corporation | $260.89 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $216.38 | 2021-2025 | Takhzyro, Cuvitru |
| Optinose US, INC. | $211.18 | 2021-2023 | |
| Ars Pharmaceuticals Operations, INC. | $181.11 | 2025 | Neffy |
| Blueprint Medicines Corporation | $133.92 | 2023 | Ayvakit |
| Leo Pharma INC. | $116.32 | 2022-2025 | Adbry, Anzupgo |
| Grifols USA, LLC | $100.33 | 2021-2024 | Xembify, Prolastin-C Liquid |
| Csl Behring | $99.83 | 2023-2025 | Hizentra, Haegarda, Andembry |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $91.70 | 2023-2025 | Inspire |
| Kaleo, INC. | $90.02 | 2021-2022 | |
| Alk-Abello, INC | $84.28 | 2021-2024 | Odactra, Grastek |
| Phathom Pharmaceuticals, INC. | $71.09 | 2024-2025 | Voquezna |
| Biocryst US Sales Co., LLC | $55.77 | 2021-2025 | Orladeyo |
| Pharming Healthcare, INC. | $41.34 | 2022-2023 | Ruconest |
| Aimmune Therapeutics, INC. | $40.32 | 2021-2022 | |
| Covis Pharma Gmbh | $26.50 | 2022 | |
| Bio Products Laboratory USA, INC. | $26.42 | 2023 | Coagadex, Gammaplex |
| Mylan Specialty L.P. | $23.42 | 2023 | Yupelri |
| Amgen INC. | $21.83 | 2025 | Tezspire |
| Galderma Laboratories, L.P. | $18.25 | 2025 | |
| Phadia US INC. | $18.01 | 2022 | |
| Pfizer INC. | $16.66 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.88 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.60 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.89 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessica Halstead listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.